Latest News
Canada’s Drug Agency has published a new position statement on the use of artificial intelligence (AI) methods in health technology assessment (HTA).
T ...
Enhancing how we involve patient organizations and people with lived experience in our work is a key ambition at Canada’s Drug Agency. As part of our ...
Now Recruiting Patient Partners for our Rare Disease Registry Request for Proposals Evaluation Panel
In March 2025, Canada’s Drug Agency launched a funding opportunity for rare disease registries to enhance their capability and implement improvement ...
Canada’s Drug Agency announces a new 5-year strategic plan, Insight to Impact 2025–2030.
This is our first strategic plan as Canada’s Drug Agency and ...
Canada’s Drug Agency has published new guidance to support newborn screening programs in Canada, which play an important role in the early diagnosis ...
Canada’s Drug Agency has launched a new funding opportunity for rare disease registries to enhance their capability and implement improvement ...
Upcoming Events
All Upcoming EventsWebinar for Patient Groups: Evolving Patient Group Input in Drug Reimbursement Reviews
Symposium 2024
Symposium 2024 is a 3-day hybrid event that gathers leaders from across Canada with expertise in policy, industry, health technology assessment, patient advocacy, medicine, public health, and communications. The theme of Symposium 2024 is From Disruption to Opportunity: Embracing Change in Health Care.
